0001093557-24-000013.txt : 20240117
0001093557-24-000013.hdr.sgml : 20240117
20240117185454
ACCESSION NUMBER: 0001093557-24-000013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240112
FILED AS OF DATE: 20240117
DATE AS OF CHANGE: 20240117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sylvain Jereme M
CENTRAL INDEX KEY: 0001681267
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51222
FILM NUMBER: 24539715
MAIL ADDRESS:
STREET 1: 6340 SEQUENCE DRIVE
CITY: SAN DIEGO
STATE: X1
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DEXCOM INC
CENTRAL INDEX KEY: 0001093557
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 330857544
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6340 SEQUENCE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8582000200
MAIL ADDRESS:
STREET 1: 6340 SEQUENCE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-01-12
0
0001093557
DEXCOM INC
DXCM
0001681267
Sylvain Jereme M
6340 SEQUENCE DRIVE
SAN DIEGO
CA
92121
0
1
0
0
EVP Chief Financial Officer
0
Common Stock
2024-01-12
4
A
0
7171
0.001
A
77239
D
Common Stock
2024-01-16
4
S
0
2734
123.6348
D
74505
D
Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2021 that vested on January 12, 2024.
Included in this number are 48,809 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
/s/ Jereme M Sylvain
2024-01-17